Notwithstanding various setbacks, various MDM2 inhibitors have now progressed into late-phase medical development. New tactics have also been formulated to boost the efficacy of MDM2 inhibitors and to mitigate their on-focus on toxicity. On this review, we summarize the development and challenges in the event of a MDM2 qualified therapy. https://abbv-74465161.bluxeblog.com/63929164/lomitapide-options